US10076520B2 - Use of tyrosine kinase inhibitor in cancer treatment - Google Patents

Use of tyrosine kinase inhibitor in cancer treatment Download PDF

Info

Publication number
US10076520B2
US10076520B2 US15/029,617 US201415029617A US10076520B2 US 10076520 B2 US10076520 B2 US 10076520B2 US 201415029617 A US201415029617 A US 201415029617A US 10076520 B2 US10076520 B2 US 10076520B2
Authority
US
United States
Prior art keywords
cancer
tki
apoptosis
radiotherapy
cancer treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US15/029,617
Other versions
US20160228436A1 (en
Inventor
Mary E. Reyland
Sten Wie
James DeGregori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado
Original Assignee
University of Colorado
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado filed Critical University of Colorado
Priority to US15/029,617 priority Critical patent/US10076520B2/en
Publication of US20160228436A1 publication Critical patent/US20160228436A1/en
Application granted granted Critical
Publication of US10076520B2 publication Critical patent/US10076520B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the present invention relates to reducing apoptosis of non-cancerous cells during a cancer treatment.
  • the present invention relates to administering a tyrosine kinase inhibitor to a cancer patient undergoing a cancer treatment in order to reduce apoptosis of non-cancerous cells.
  • Cancer is one of the leading causes of death. However, with the early detection and treatment, many cancer patients can live a long productive life. Unfortunately, cancer treatment can be extremely painful or discomforting to cancer patients. Some cancer patients even stop cancer treatment due to extreme pain and/or discomfort during treatment.
  • Cancer treatment typically involves a relatively indiscriminate killing of both cancerous cells and non-cancerous, e.g., normal, cells. Many side-effects of cancer treatment can be attributed to killing of non-cancerous cells during cancer treatment. It is believed that many, if not all, of the undesirable side-effects of cancer treatment are in large part due to apoptosis of non-cancerous cells due to cancer treatment.
  • Some aspects of the invention provide a method for reducing apoptosis of non-cancerous cells during a cancer treatment, said method comprising administering a therapeutically effective amount of a tyrosine kinase inhibitor prior to administering a cancer treatment to a cancer patient.
  • Another aspects of the invention provide a method for treating a cancer patient, said method comprising administering a tyrosine kinase inhibitor to a cancer patient prior to administering a cancer treatment to protect noncancerous cells from said cancer treatment, wherein administration of said tyrosine kinase inhibitor significantly reduces the amount of apoptosis of noncancerous cells.
  • Yet other aspects of the invention provide a method for reducing a side-effect of a cancer treatment in a cancer patient, said method comprising administering a tyrosine kinase inhibitor to said cancer patient prior to administering a cancer treatment to said patient.
  • FIG. 1 is a schematic illustration showing role of tyrosine phosphorylation of PKC ⁇ in apoptosis.
  • Panel A shows structure of PKC ⁇ showing positions of Y64, Y155, caspase cleavage and the NLS.
  • Panel B shows a schematic illustration of current model of PKC ⁇ and salivary acinar cell apoptosis.
  • FIG. 2 shows results of treating cells with tyrosine kinase inhibitors, i.e., TKIs, (e.g., dasatinib and imatinib) prior to exposing the cells to a cytotoxic agent hydrogen peroxide.
  • TKIs tyrosine kinase inhibitors
  • dasatinib suppresses phosphorylation of PKC ⁇ at Y155, Y64 and Y311 in cells treated with H 2 O 2 .
  • Panel A also shows imatinib suppresses phosphorylation of PKC ⁇ at Y155 in cells treated with H 2 O 2 .
  • both drugs block importin- ⁇ binding (data not shown for imatinib).
  • FIG. 3A shows the results of ParC5 cells that were treated with DMSO (C), Imatinib (I), Dasatinib (D), 50 ⁇ M of etoposide (E), or the combination of etoposide and inhibitors as indicated prior to irradiation.
  • FIG. 3B shows the relative caspase-3 activity of ParC5 cells after irradiation at various radiation levels.
  • Left bars are caspace-3 activity of cells that were left untreated and the right bars are caspase-3 activity of cells that were pre-treated with Dasatinib (20 nM) prior to irradiation.
  • FIG. 3C shows results of suppression of apoptosis in the irradiated salivary gland in mice treated with dasatinib.
  • FIG. 4 is a bar graph showing that the TKIs, dasatinib, imatinib, saracatinib and ponatinib, all inhibit irradiation induced apoptosis.
  • FIG. 5 shows experimental procedure time line (Panel A) and the results of administering Tyrosine Kinase Inhibitor prior to administering radiation to mice (Panels B, C and D).
  • the isoforms of the protein kinase C (“PKC”) family are activated in response to various stimuli (e.g., mitogenic stimuli, to inflammatory stimuli, and to stress) and play important roles in a variety of cellular functions including apoptosis.
  • PKC ⁇ a member of the novel PKC subfamily, is actively involved in cell apoptosis in a stimulus and tissue specific manner. It is believed that PKC ⁇ both regulates the expression and function of apoptosis related proteins and is itself a target for caspases.
  • phosphorylation of PKC ⁇ on distinct tyrosine residues and its association with specific apoptotic related proteins such as c-Abl, DNA-PK, p73 and lamin B are pivotal to its function in cell apoptosis.
  • tyrosine phosphorylation and importin- ⁇ binding are key regulatory steps in apoptosis as they control nuclear import.
  • caspase in particular caspase 3
  • cleavage of PKC ⁇ is thought to amplify the apoptotic response.
  • cancer treatment includes radiotherapy and chemotherapy to treat cancer.
  • Some aspects of the invention provide a method for reducing apoptosis of non-cancerous cells during a cancer treatment.
  • the method comprises administering a therapeutically effective amount of a tyrosine kinase inhibitor (“TKI”) prior to administering a cancer treatment to a cancer patient.
  • TKI tyrosine kinase inhibitor
  • the term “reducing apoptosis of non-cancerous cells” refers to reducing at least 30%, typically at least 60%, and often at least 80% of non-cancerous cell apoptosis using the method of the invention relative to cancer treatment that does not include administration of a TKI prior to cancer treatment.
  • the TKI is administered at least 30 min, typically at least 45 min, and often at least 60 min prior to administering cancer treatment to a cancer patient.
  • the method further comprises administering a second TKI after administering said cancer treatment to said cancer patient.
  • the second TKI can be the same as the TKI that is administered prior to cancer treatment or it can be a different TKI.
  • the same TKI is used pre- and post-cancer treatment.
  • a TKI is administered after cancer treatment, typically it is administered within 60 min, often within 120 min, and most often within 180 min after cancer treatment.
  • said steps of administering said tyrosine kinase inhibitor prior to said cancer treatment reduces apoptosis of non-cancerous cells by at least 30%, typically by at least 60%, and often by at least 80%.
  • said cancer treatment consists of radiotherapy. In other embodiments, said cancer treatment consists of chemotherapy.
  • said cancer treatment consists of combination of radiotherapy and chemotherapy.
  • said TKI can also be administered between chemotherapy and radiotherapy sessions.
  • said tyrosine kinase inhibitor inhibits c-Abl and/or Src-family kinases.
  • Exemplary tyrosine kinase inhibitors that are useful in methods of the invention include, but are not limited to, dasatinib, imatinib, ponatinib, saracatinib, lapatinb, gefitinib, sorafenib, erlotinib, sunitinib, nilotinib, vandetanib, bosutinib, afatinib and regorafenib.
  • methods of the invention can be used in preventing apoptosis of non-cancerous cells in cancer treatment for any type of cancer.
  • Exemplary cancers for which methods of the invention is useful include, but are not limited to, head and neck cancer, pancreatic cancer, stomach cancer, breast cancer, colon cancer, lung cancer, liver cancer, leukemia, bone cancer, ovarian cancer, cervical cancer, brain cancer, skin cancer, prostate cancer, thyroid cancer, etc.
  • aspects of the invention include methods for treating a cancer patient. Such methods include administering a tyrosine kinase inhibitor to a cancer patient prior to administering a cancer treatment to protect non-cancerous cells from said cancer treatment, wherein administration of said tyrosine kinase inhibitor significantly reduces the amount of apoptosis of non-cancerous cells.
  • the tyrosine kinase is administered to the cancer patient prior to administering cancer treatment.
  • the tyrosine kinase inhibitor can also be administered post cancer treatment as discussed above.
  • Yet other aspects of the invention include methods for reducing a side-effect of a cancer treatment in a cancer patient.
  • Such methods include administering a therapeutically effective amount of tyrosine kinase inhibitor to said cancer patient prior to administering a cancer treatment.
  • therapeutically effective amount means the amount of a TKI that, when administered to a cancer patient, is sufficient to reduce apoptosis of non-cancerous cells.
  • the “therapeutically effective amount” will vary depending on the TKI, the severity of cancer treatment and the age, weight, etc., of the cancer patient.
  • tyrosine kinase inhibitors inhibit irradiation-induced and chemotherapy-induced (e.g., etoposide-induced) apoptosis of cells in vivo as well as cultured rat salivary acinar cells (cell line ParC5). These inhibitors block tyrosine phosphorylation of PKC ⁇ and its import into the nucleus. Without being bound by any theory, since nuclear import of PKC ⁇ is required for apoptosis, this is believed to be at least one of the mechanisms of action by which TKIs inhibit apoptosis of non-cancerous cells. Based on the magnitude of apoptosis inhibition (e.g., >80% in some instances), additional targets or mechanisms are believed to be likely.
  • chemotherapy-induced e.g., etoposide-induced
  • the TKI is administered in formulations including those suitable for oral (including buccal and sub-lingual), rectal, nasal, topical, pulmonary, vaginal, or parenteral (including intramuscular, intraarterial, intrathecal, subcutaneous and intravenous) administration or in a form suitable for administration by inhalation or insufflation.
  • the TKI is administered by direct injection at or near the site of radio- or chemo-therapy.
  • ParC5 cells were pre-treated with dasatinib or imatinib for 30 mins prior to addition of hydrogen peroxide to induce apoptosis. Cell lysates were probed by immunoblot as indicated. Hydrogen peroxide induced phosphorylation of PKC ⁇ at tyrosine 64 (Y64), tyrosine 155 (Y155) and tyrosine 311 (Y311). Pretreatment of cells with dasatinib (Panel A of FIG. 2 , left) inhibited phosphorylation of PKC ⁇ at all sites, consistent with inhibition of both c-Src and c-Abl activation as assayed using antibodies to pY412Abl and pY416Src. Pane A of FIG. 2 , right, shows a similar experiment in which ParC5 cells were pre-treated with imatinib. In this experiment imatinib inhibited phosphorylation of PKC ⁇ at Y155 only.
  • 293T cells were transfected with pGFP-PKC ⁇ .
  • Transfected cells were left untreated, or pre-treated with dasatinib prior to treatment with hydrogen peroxide. Lysates were incubated with an anti-GFP to immunoprecipitate GFPPKC ⁇ and immunobloted for importin- ⁇ . The results are shown in panel B of FIG. 2 . While importin- ⁇ immunoprecipitated with PKC ⁇ in cells treated with hydrogen peroxide, this interaction did not occur in cells pre-treated with dasatinib. Similar results were seen when cells were pretreated with imatinib (data not shown)
  • ParC5 cells were treated with DMSO (control), imatinib, dasatinib, or 50 ⁇ M of etoposide or the combination of etoposide and tyrosine kinase inhibitors (TKIs). TKIs were added to cells 30 mins prior to addition of etoposide. Relative caspase-3 activity for each was measured, which is indicative of apoptosis. As shown in FIG. 3A , imatinib and dasatinib both significantly reduced apoptosis.
  • ParC5 cells were left untreated or pre-treated with 20 nM of dasatinib 30 mins prior to irradiation (5, 7.5 or 10 Gy). Relative caspase-3 activity was measured and are shown in FIG. 3B . As can be seen, dasatinib significantly reduced apoptosis of cells.
  • mice were treated with DMSO or 20 mg/kg of dasatinib in DMSO 1 hr prior and 3 hr post irradiation (25 Gy) by oral gavage. The mice were sacrificed 24 hrs later. Parotid gland tissue was stained with anti-act caspase 3 and cells with active caspase-3 were quantified. Average of three mice (>1000 cells per mouse) are shown in FIG. 3C . In FIG. 3C , the data is expressed as % positive/total cells (p ⁇ 0.01).
  • Parotid salivary acinar cells (parC5) were pre-treated with dasatinib, imatinib, saracatinib or ponatinib 30 mins prior to 10 Gy irradiation. Cells were harvested after an additional 18 hrs and casapase 3 activity were measured. As can be seen in FIG. 4 (p ⁇ 0.05), all TKI treated cells showed a significant protection from apoptosis.
  • mice were irradiated to the head and neck using a cesium-137 source, with or without administration of dasatinib (20 mg/kg), imatinib (50 mg/kg), or bosutinib (100 mg/kg) by oral gavage 1 hour before and 3 hours after irradiation (see schematic in FIG. 5 , panel A, which shows a schematic representation of the experiment outlining times of oral gavage, radiation and saliva collection). The rest of the mouse body was protected by lead shielding.
  • mice were gavaged with vehicle alone for dasatinib (80 mM citric acid buffer, pH 2.1) imatinib (water) or bosutinib (0.5% methocel and 0.4% Tween 80). Mouse weight and saliva flow rates were measured prior to irradiation and every 30 days up to 90 days). A minimum of 3 mice were used for each condition in each experiment.
  • mice were given an intraperitoneal injection of carbachol dissolved in saline (0.25 mg/kg) two minutes prior to measuring salivary flow rate. Saliva was collected for 3 min using a micropipette. Salivary flow rates are expressed as mL/min.
  • Panels B and C in FIG. 5 show the results of mice that were irradiated with 10 Gy to the head and neck, with or without the administration of dasatinib (Panel B) and imatinib (Panel C).
  • Panel D in FIG. 5 shows the results of mice that were irradiated with 15 Gy to the head and neck, with or without the administration of bosutinib.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides methods for reducing apoptosis of non-cancerous cells during a cancer treatment and beneficial effects associated with reducing such apoptosis. In particular, methods of the invention comprise administering a tyrosine kinase inhibitor to a cancer patient who is undergoing cancer treatment in order to reduce apoptosis of non-cancerous cells.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims the priority benefit of U.S. Provisional Application No. 61/893,132, filed Oct. 18, 2013, which is incorporated herein by reference in its entirety.
STATEMENT REGARDING FEDERALLY FUNDED RESEARCH
This invention was made with government support under grant number DE015648 awarded by the National Institutes of Health. The government has certain rights in the invention.
FIELD OF THE INVENTION
The present invention relates to reducing apoptosis of non-cancerous cells during a cancer treatment. In particular, the present invention relates to administering a tyrosine kinase inhibitor to a cancer patient undergoing a cancer treatment in order to reduce apoptosis of non-cancerous cells.
BACKGROUND OF THE INVENTION
Cancer is one of the leading causes of death. However, with the early detection and treatment, many cancer patients can live a long productive life. Unfortunately, cancer treatment can be extremely painful or discomforting to cancer patients. Some cancer patients even stop cancer treatment due to extreme pain and/or discomfort during treatment.
Cancer treatment typically involves a relatively indiscriminate killing of both cancerous cells and non-cancerous, e.g., normal, cells. Many side-effects of cancer treatment can be attributed to killing of non-cancerous cells during cancer treatment. It is believed that many, if not all, of the undesirable side-effects of cancer treatment are in large part due to apoptosis of non-cancerous cells due to cancer treatment.
While some cancer treatments have been developed that target mainly the cancerous cells, such treatments are not widely available, are often time consuming, or require additional laboratory work.
Therefore, there is a need for a general method for reducing apoptosis of non-cancerous cells during cancer treatment to reduce the side-effects of cancer treatment due to apoptosis of non-cancerous cells during such a treatment.
SUMMARY OF THE INVENTION
Some aspects of the invention provide a method for reducing apoptosis of non-cancerous cells during a cancer treatment, said method comprising administering a therapeutically effective amount of a tyrosine kinase inhibitor prior to administering a cancer treatment to a cancer patient.
Another aspects of the invention provide a method for treating a cancer patient, said method comprising administering a tyrosine kinase inhibitor to a cancer patient prior to administering a cancer treatment to protect noncancerous cells from said cancer treatment, wherein administration of said tyrosine kinase inhibitor significantly reduces the amount of apoptosis of noncancerous cells.
Yet other aspects of the invention provide a method for reducing a side-effect of a cancer treatment in a cancer patient, said method comprising administering a tyrosine kinase inhibitor to said cancer patient prior to administering a cancer treatment to said patient.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a schematic illustration showing role of tyrosine phosphorylation of PKCδ in apoptosis. Panel A shows structure of PKCδ showing positions of Y64, Y155, caspase cleavage and the NLS. Panel B shows a schematic illustration of current model of PKCδ and salivary acinar cell apoptosis.
FIG. 2 shows results of treating cells with tyrosine kinase inhibitors, i.e., TKIs, (e.g., dasatinib and imatinib) prior to exposing the cells to a cytotoxic agent hydrogen peroxide. As can be seen in panel A, dasatinib suppresses phosphorylation of PKCδ at Y155, Y64 and Y311 in cells treated with H2O2. Panel A also shows imatinib suppresses phosphorylation of PKCδ at Y155 in cells treated with H2O2. As seen in Panel B, both drugs block importin-α binding (data not shown for imatinib).
FIG. 3A shows the results of ParC5 cells that were treated with DMSO (C), Imatinib (I), Dasatinib (D), 50 μM of etoposide (E), or the combination of etoposide and inhibitors as indicated prior to irradiation.
FIG. 3B shows the relative caspase-3 activity of ParC5 cells after irradiation at various radiation levels. Left bars are caspace-3 activity of cells that were left untreated and the right bars are caspase-3 activity of cells that were pre-treated with Dasatinib (20 nM) prior to irradiation.
FIG. 3C shows results of suppression of apoptosis in the irradiated salivary gland in mice treated with dasatinib.
FIG. 4 is a bar graph showing that the TKIs, dasatinib, imatinib, saracatinib and ponatinib, all inhibit irradiation induced apoptosis.
FIG. 5 shows experimental procedure time line (Panel A) and the results of administering Tyrosine Kinase Inhibitor prior to administering radiation to mice (Panels B, C and D).
 DETAILED DESCRIPTION OF THE INVENTION
The isoforms of the protein kinase C (“PKC”) family are activated in response to various stimuli (e.g., mitogenic stimuli, to inflammatory stimuli, and to stress) and play important roles in a variety of cellular functions including apoptosis. In particular, PKCδ a member of the novel PKC subfamily, is actively involved in cell apoptosis in a stimulus and tissue specific manner. It is believed that PKCδ both regulates the expression and function of apoptosis related proteins and is itself a target for caspases. In addition, it is believed phosphorylation of PKCδ on distinct tyrosine residues and its association with specific apoptotic related proteins such as c-Abl, DNA-PK, p73 and lamin B are pivotal to its function in cell apoptosis. In particular, as shown in FIG. 1, it is believed tyrosine phosphorylation and importin-α binding are key regulatory steps in apoptosis as they control nuclear import. Moreover, caspase (in particular caspase 3) cleavage of PKCδ is thought to amplify the apoptotic response.
Referring again to FIG. 1, it is believed that activation of c-Abl- or Src-family of kinases stimulates apoptosis. While apoptosis can be a part of natural process, in cancer treatment apoptosis of non-cancerous cells have been shown to be one of the main causes of cancer treatment side-effects. Thus, it is believed that by reducing apoptosis of non-cancerous cells one can significantly reduce the side-effects of cancer treatment. As used herein, the term “cancer treatment” includes radiotherapy and chemotherapy to treat cancer.
Some aspects of the invention provide a method for reducing apoptosis of non-cancerous cells during a cancer treatment. Typically, the method comprises administering a therapeutically effective amount of a tyrosine kinase inhibitor (“TKI”) prior to administering a cancer treatment to a cancer patient. As used herein, the term “reducing apoptosis of non-cancerous cells” refers to reducing at least 30%, typically at least 60%, and often at least 80% of non-cancerous cell apoptosis using the method of the invention relative to cancer treatment that does not include administration of a TKI prior to cancer treatment. Typically, the TKI is administered at least 30 min, typically at least 45 min, and often at least 60 min prior to administering cancer treatment to a cancer patient.
In some embodiments, the method further comprises administering a second TKI after administering said cancer treatment to said cancer patient. The second TKI can be the same as the TKI that is administered prior to cancer treatment or it can be a different TKI. Typically, the same TKI is used pre- and post-cancer treatment. When a TKI is administered after cancer treatment, typically it is administered within 60 min, often within 120 min, and most often within 180 min after cancer treatment.
Still in other embodiments, said steps of administering said tyrosine kinase inhibitor prior to said cancer treatment reduces apoptosis of non-cancerous cells by at least 30%, typically by at least 60%, and often by at least 80%.
Yet in other embodiments, said cancer treatment consists of radiotherapy. In other embodiments, said cancer treatment consists of chemotherapy.
Still in other embodiments, said cancer treatment consists of combination of radiotherapy and chemotherapy. In such embodiments, said TKI can also be administered between chemotherapy and radiotherapy sessions.
Typically, said tyrosine kinase inhibitor inhibits c-Abl and/or Src-family kinases.
Exemplary tyrosine kinase inhibitors that are useful in methods of the invention include, but are not limited to, dasatinib, imatinib, ponatinib, saracatinib, lapatinb, gefitinib, sorafenib, erlotinib, sunitinib, nilotinib, vandetanib, bosutinib, afatinib and regorafenib.
Generally, methods of the invention can be used in preventing apoptosis of non-cancerous cells in cancer treatment for any type of cancer. Exemplary cancers for which methods of the invention is useful include, but are not limited to, head and neck cancer, pancreatic cancer, stomach cancer, breast cancer, colon cancer, lung cancer, liver cancer, leukemia, bone cancer, ovarian cancer, cervical cancer, brain cancer, skin cancer, prostate cancer, thyroid cancer, etc.
Other aspects of the invention include methods for treating a cancer patient. Such methods include administering a tyrosine kinase inhibitor to a cancer patient prior to administering a cancer treatment to protect non-cancerous cells from said cancer treatment, wherein administration of said tyrosine kinase inhibitor significantly reduces the amount of apoptosis of non-cancerous cells. Typically, the tyrosine kinase is administered to the cancer patient prior to administering cancer treatment. In some cases, the tyrosine kinase inhibitor can also be administered post cancer treatment as discussed above.
Yet other aspects of the invention include methods for reducing a side-effect of a cancer treatment in a cancer patient. Such methods include administering a therapeutically effective amount of tyrosine kinase inhibitor to said cancer patient prior to administering a cancer treatment. As used herein, the term “therapeutically effective amount” means the amount of a TKI that, when administered to a cancer patient, is sufficient to reduce apoptosis of non-cancerous cells. The “therapeutically effective amount” will vary depending on the TKI, the severity of cancer treatment and the age, weight, etc., of the cancer patient.
As shown in the Examples section, the present inventors have discovered that tyrosine kinase inhibitors inhibit irradiation-induced and chemotherapy-induced (e.g., etoposide-induced) apoptosis of cells in vivo as well as cultured rat salivary acinar cells (cell line ParC5). These inhibitors block tyrosine phosphorylation of PKCδ and its import into the nucleus. Without being bound by any theory, since nuclear import of PKCδ is required for apoptosis, this is believed to be at least one of the mechanisms of action by which TKIs inhibit apoptosis of non-cancerous cells. Based on the magnitude of apoptosis inhibition (e.g., >80% in some instances), additional targets or mechanisms are believed to be likely.
Typically, the TKI is administered in formulations including those suitable for oral (including buccal and sub-lingual), rectal, nasal, topical, pulmonary, vaginal, or parenteral (including intramuscular, intraarterial, intrathecal, subcutaneous and intravenous) administration or in a form suitable for administration by inhalation or insufflation. In some embodiments, the TKI is administered by direct injection at or near the site of radio- or chemo-therapy.
Additional objects, advantages, and novel features of this invention will become apparent to those skilled in the art upon examination of the following examples thereof, which are not intended to be limiting. In the Examples, procedures that are constructively reduced to practice are described in the present tense, and procedures that have been carried out in the laboratory are set forth in the past tense.
EXAMPLES Example 1
ParC5 cells were pre-treated with dasatinib or imatinib for 30 mins prior to addition of hydrogen peroxide to induce apoptosis. Cell lysates were probed by immunoblot as indicated. Hydrogen peroxide induced phosphorylation of PKCδ at tyrosine 64 (Y64), tyrosine 155 (Y155) and tyrosine 311 (Y311). Pretreatment of cells with dasatinib (Panel A of FIG. 2, left) inhibited phosphorylation of PKCδ at all sites, consistent with inhibition of both c-Src and c-Abl activation as assayed using antibodies to pY412Abl and pY416Src. Pane A of FIG. 2, right, shows a similar experiment in which ParC5 cells were pre-treated with imatinib. In this experiment imatinib inhibited phosphorylation of PKCδ at Y155 only.
293T cells were transfected with pGFP-PKCδ. Transfected cells were left untreated, or pre-treated with dasatinib prior to treatment with hydrogen peroxide. Lysates were incubated with an anti-GFP to immunoprecipitate GFPPKCδ and immunobloted for importin-α. The results are shown in panel B of FIG. 2. While importin-α immunoprecipitated with PKCδ in cells treated with hydrogen peroxide, this interaction did not occur in cells pre-treated with dasatinib. Similar results were seen when cells were pretreated with imatinib (data not shown)
Example 2
ParC5 cells were treated with DMSO (control), imatinib, dasatinib, or 50 μM of etoposide or the combination of etoposide and tyrosine kinase inhibitors (TKIs). TKIs were added to cells 30 mins prior to addition of etoposide. Relative caspase-3 activity for each was measured, which is indicative of apoptosis. As shown in FIG. 3A, imatinib and dasatinib both significantly reduced apoptosis.
ParC5 cells were left untreated or pre-treated with 20 nM of dasatinib 30 mins prior to irradiation (5, 7.5 or 10 Gy). Relative caspase-3 activity was measured and are shown in FIG. 3B. As can be seen, dasatinib significantly reduced apoptosis of cells.
Mice were treated with DMSO or 20 mg/kg of dasatinib in DMSO 1 hr prior and 3 hr post irradiation (25 Gy) by oral gavage. The mice were sacrificed 24 hrs later. Parotid gland tissue was stained with anti-act caspase 3 and cells with active caspase-3 were quantified. Average of three mice (>1000 cells per mouse) are shown in FIG. 3C. In FIG. 3C, the data is expressed as % positive/total cells (p<0.01).
Example 3
Parotid salivary acinar cells (parC5) were pre-treated with dasatinib, imatinib, saracatinib or ponatinib 30 mins prior to 10 Gy irradiation. Cells were harvested after an additional 18 hrs and casapase 3 activity were measured. As can be seen in FIG. 4 (p<0.05), all TKI treated cells showed a significant protection from apoptosis.
Example 4
The efficacy of three tyrosine kinase inhibitors was examined as radio-protectors in the salivary gland in vivo. Briefly, mice were irradiated to the head and neck using a cesium-137 source, with or without administration of dasatinib (20 mg/kg), imatinib (50 mg/kg), or bosutinib (100 mg/kg) by oral gavage 1 hour before and 3 hours after irradiation (see schematic in FIG. 5, panel A, which shows a schematic representation of the experiment outlining times of oral gavage, radiation and saliva collection). The rest of the mouse body was protected by lead shielding. Control mice were gavaged with vehicle alone for dasatinib (80 mM citric acid buffer, pH 2.1) imatinib (water) or bosutinib (0.5% methocel and 0.4% Tween 80). Mouse weight and saliva flow rates were measured prior to irradiation and every 30 days up to 90 days). A minimum of 3 mice were used for each condition in each experiment.
To stimulate salivation, mice were given an intraperitoneal injection of carbachol dissolved in saline (0.25 mg/kg) two minutes prior to measuring salivary flow rate. Saliva was collected for 3 min using a micropipette. Salivary flow rates are expressed as mL/min.
As shown in FIG. 5 these tyrosine kinase inhibitors preserved salivary gland function following radiation. Panels B and C in FIG. 5 show the results of mice that were irradiated with 10 Gy to the head and neck, with or without the administration of dasatinib (Panel B) and imatinib (Panel C). Panel D in FIG. 5 shows the results of mice that were irradiated with 15 Gy to the head and neck, with or without the administration of bosutinib. A minimum of 3 mice were used for each condition (n=3) and the data represents the average saliva flow rate +/− the standard deviation (asterisk indicates a p value <0.01).
The foregoing discussion of the invention has been presented for purposes of illustration and description. The foregoing is not intended to limit the invention to the form or forms disclosed herein. Although the description of the invention has included description of one or more embodiments and certain variations and modifications, other variations and modifications are within the scope of the invention, e.g., as may be within the skill and knowledge of those in the art, after understanding the present disclosure. It is intended to obtain rights which include alternative embodiments to the extent permitted, including alternate, interchangeable and/or equivalent structures, functions, ranges or steps to those claimed, whether or not such alternate, interchangeable and/or equivalent structures, functions, ranges or steps are disclosed herein, and without intending to publicly dedicate any patentable subject matter.

Claims (9)

What is claimed is:
1. A method for reducing apoptosis of non-cancerous cells in a cancer patient during a radiotherapy, said method comprising administering a therapeutically effective amount of a tyrosine kinase inhibitor (TKI) that inhibits c-Abl and Src-family kinases to a cancer patient prior to administering a radiotherapy treatment, wherein administration of said TKI reduces the amount of apoptosis of non-cancerous cells compared to receiving said radiotherapy treatment in the absence of said prior administration of said TKI.
2. The method of claim 1, wherein said TKI is selected from the group consisting of dasatinib, imatinib, ponatinib, saracatinib, and a combination thereof.
3. The method of claim 1 further comprising the step of administering a second tyrosine kinase inhibitor to said cancer patient after administering said radiation cancer therapy.
4. The method of claim 1, wherein said cancer comprises head and neck cancer.
5. The method of claim 4, wherein said TKI reduces apoptosis of non-cancerous cells in salivary glands.
6. A method for protecting non-cancerous cells in salivary glands during a radiotherapy in a patient suffering from a head and neck cancer, said method comprising administering a therapeutically effective amount of a tyrosine kinase inhibitor (TKI) that inhibits c-Abl and Src-family kinases to a cancer patient undergoing a radiotherapy cancer treatment, wherein administration of said TKI reduces the amount of apoptosis of non-cancerous cells in salivary glands of said patient compared to receiving the radiotherapy in the absence of administration of said TKI.
7. The method of claim 6, wherein said TKI is administered prior to administration of the radiotherapy.
8. The method of claim 6, wherein said TKI is administered after administration of the radiotherapy.
9. The method of claim 6, wherein TKI is administered before and after administration of the radiotherapy.
US15/029,617 2013-10-18 2014-10-17 Use of tyrosine kinase inhibitor in cancer treatment Active US10076520B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/029,617 US10076520B2 (en) 2013-10-18 2014-10-17 Use of tyrosine kinase inhibitor in cancer treatment

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361893132P 2013-10-18 2013-10-18
PCT/US2014/061038 WO2015058034A1 (en) 2013-10-18 2014-10-17 Use of tyrosine kinase inhibitor in cancer treatment
US15/029,617 US10076520B2 (en) 2013-10-18 2014-10-17 Use of tyrosine kinase inhibitor in cancer treatment

Publications (2)

Publication Number Publication Date
US20160228436A1 US20160228436A1 (en) 2016-08-11
US10076520B2 true US10076520B2 (en) 2018-09-18

Family

ID=52828717

Family Applications (1)

Application Number Title Priority Date Filing Date
US15/029,617 Active US10076520B2 (en) 2013-10-18 2014-10-17 Use of tyrosine kinase inhibitor in cancer treatment

Country Status (2)

Country Link
US (1) US10076520B2 (en)
WO (1) WO2015058034A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10940149B1 (en) 2018-06-15 2021-03-09 Handa Oncology, Llc Kinase inhibitor salts and compositions thereof
US11376247B2 (en) * 2017-06-05 2022-07-05 The Regents Of The University Of Colorado, A Body Corporate Tyrosine kinase inhibitors regenerate non-cancerous tissue after cancer therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120295917A1 (en) * 2009-12-28 2012-11-22 Celltrion Pharm, Inc. Imatinib dichloroacetate and anti-cancer agent comprising the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011092338A1 (en) * 2010-02-01 2011-08-04 Ab Science Combined treatment of pancreatic cancer with gemcitabine and masitinib

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120295917A1 (en) * 2009-12-28 2012-11-22 Celltrion Pharm, Inc. Imatinib dichloroacetate and anti-cancer agent comprising the same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Arora (The Journal of Pharmacology and Experimental Therapeutics; 315(3), 971-979, 2005). *
Boehrer (cell Cycle; 10:18, 3168-3175; Sep. 15, 2011). *
Riely (Journal of Clinical Oncology; vol. 27, No. 2, 264-270, Jan. 10, 2009). *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11376247B2 (en) * 2017-06-05 2022-07-05 The Regents Of The University Of Colorado, A Body Corporate Tyrosine kinase inhibitors regenerate non-cancerous tissue after cancer therapy
US10940149B1 (en) 2018-06-15 2021-03-09 Handa Oncology, Llc Kinase inhibitor salts and compositions thereof
US11007195B2 (en) 2018-06-15 2021-05-18 Handa Oncology, Llc Kinase inhibitor salts, and compositions thereof
US11052088B2 (en) 2018-06-15 2021-07-06 Handa Oncology, Llc Kinase inhibitor salts, and compositions thereof
US11160805B2 (en) 2018-06-15 2021-11-02 Handa Onocology, Llc Kinase inhibitor salts and compositions thereof
US12064428B2 (en) 2018-06-15 2024-08-20 Handa Oncology, Llc Kinase inhibitor salts and compositions thereof
US12064430B2 (en) 2018-06-15 2024-08-20 Handa Oncology, Llc Kinase inhibitor salts and compositions thereof

Also Published As

Publication number Publication date
US20160228436A1 (en) 2016-08-11
WO2015058034A1 (en) 2015-04-23

Similar Documents

Publication Publication Date Title
O'Brien et al. Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models
Kubicek et al. Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies
Wang et al. Sestrin2 overexpression attenuates focal cerebral ischemic injury in rat by increasing Nrf2/HO-1 pathway-mediated angiogenesis
Pretto et al. Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle
Rios et al. Durable response of glioblastoma to adjuvant therapy consisting of temozolomide and a weekly dose of AMD3100 (plerixafor), a CXCR4 inhibitor, together with lapatinib, metformin and niacinamide
US20160243232A1 (en) Prostate cancer treatment
Tsai et al. S onic H edgehog inhibition as a strategy to augment radiosensitivity of hepatocellular carcinoma
Beauchesne et al. Human malignant glioma cell lines are sensitive to low radiation doses
Han et al. Serotonin7 receptors in the lateral habenular nucleus regulate depressive-like behaviors in the hemiparkinsonian rats
US10076520B2 (en) Use of tyrosine kinase inhibitor in cancer treatment
Kim et al. Nucleocytoplasmic p27Kip1 export is required for ERK1/2-mediated reactive astroglial proliferation following status epilepticus
Shen et al. Bruton’s tyrosine kinase inhibitors in the treatment of primary central nervous system lymphoma: A mini-review
San Martín et al. Sonidegib in the treatment of locally advanced Basal Cell Carcinoma
US10639296B2 (en) Methods to mitigate injury from radiation exposure
Xu et al. Mechanisms of the PD-1/PD-L1 pathway in itch: From acute itch model establishment to the role in chronic itch in mouse
US9345704B2 (en) Materials and methods for suppressing and/or treating neurofibroma and related tumors
Danciulescu et al. Temozolomide and targeted therapy against epidermal growth factor receptor in glioma
Rajagopalan et al. Radiosensitizer Sanazole (AK-2123) enhances γ-radiation-induced Apoptosis in murine fibrosarcoma
Wang et al. Protective mechanism of electroacupuncture on peripheral neurotoxicity induced by oxaliplatin in rats
US20210023107A1 (en) USE OF 6-THIO-dG TO TREAT THERAPY-RESISTANT TELOMERASEPOSITIVE PEDIATRIC BRAIN TUMORS
Agarwal et al. Radiation-induced xerostomia
Li et al. A pilot study of conformal radiotherapy combined with erlotinib-based multimodality therapy in newly diagnosed metastatic non-small-cell lung cancer.
Pietraszkiewicz et al. UTL-5g lowers levels of TGF-β and TNF-α elevated by lung irradiation and does not affect tumorresponse to irradiation
CN110151748A (en) It is a kind of for treating the pharmaceutical composition of prostate cancer
Juloori et al. Glioblastoma

Legal Events

Date Code Title Description
STCF Information on status: patent grant

Free format text: PATENTED CASE

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FEPP Fee payment procedure

Free format text: SURCHARGE FOR LATE PAYMENT, SMALL ENTITY (ORIGINAL EVENT CODE: M2554); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 4